Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SNDX | US
-0.62
-3.19%
Healthcare
Biotechnology
30/06/2024
04/10/2024
18.82
18.83
19.10
18.72
Syndax Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613 which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab a monoclonal antibody that blocks the colony stimulating factor 1 or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing development and commercialization of Entinostat. Syndax Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Waltham Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
40.8%1 month
45.2%3 months
46.7%6 months
41.9%-
-
3.70
0.00
0.00
-105.26
336.10
-
-287.98M
1.60B
1.60B
-
-2.12K
-
33.30K
-63.30
10.91
11.46
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.22
Range1M
3.10
Range3M
7.73
Rel. volume
0.46
Price X volume
10.53M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 24.48 | 1.74B | -0.20% | n/a | 2.62% |
Recursion Pharmaceuticals Inc. Class A Common Stock | RXRX | Biotechnology | 6.11 | 1.72B | 0.00% | n/a | 15.38% |
Arvinas Inc | ARVN | Biotechnology | 24.96 | 1.71B | 1.05% | n/a | 0.38% |
PROK | PROK | Biotechnology | 1.695 | 1.65B | 3.04% | n/a | -0.69% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 23.6 | 1.63B | 4.61% | n/a | 4.89% |
Ardelyx Inc | ARDX | Biotechnology | 6.82 | 1.61B | -1.59% | n/a | 71.36% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 7.58 | 1.57B | 2.71% | n/a | -178.85% |
Belite Bio Inc | BLTE | Biotechnology | 50.99 | 1.56B | 4.68% | n/a | 0.00% |
Immunocore Holdings plc | IMCR | Biotechnology | 31.11 | 1.56B | 0.06% | n/a | 131.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -105.26 | 0.76 | Cheaper |
Ent. to Revenue | 336.10 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.70 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 46.69 | 74.67 | Lower Risk |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 1.60B | 3.73B | Emerging |